Additionally, myocyte enhancer factor-2D (MEF2D) rearrangements, such as the MEF2D-HNRNPU1 (MH) fusion, aberrantly activate MEF2D’s transcriptional activity, disrupt the expression of genes related to B-cell development, and promote the malignant proliferation of leukemia cells [97]. This evidence concerns the gene MEF2D and leukemia.